An experimental drug that combines two commonly used treatments helped quell migraine symptoms better than either one alone, a new U.S. study released Tuesday suggested.
The research, published in this week's Journal of the American Medical Association, tested experimental drug combination Trexima against either drug used alone.
Pozen Inc. is developing Trexima with British drugmaker GlaxoSmithKline's. The drug combines Glaxo's popular migraine drug Imitrex -- known generically as sumatriptan -- with the older painkiller naproxen sodium.
The drug combo attacks different pathways in the brain believed to contribute to migraines, which affect more than 28 million people in the United States. Migraine symptoms include throbbing headache pain, nausea, vomiting and sensitivity to light and sound.
The multibillion-dollar market for prescription migraine drugs is dominated by a class know as triptans, of which Glaxo's Imitrex is the most widely used.
Source: CNN
Something like this can get fast tracked by the FDA and in patient use in a very short time. If you suffer from migraines, this is good news.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment